Strong performance for Medivation Inc.’s late-stage prostate cancer drug MDV3100 on all secondary efficacy endpoints in the Phase III AFFIRM trial, with adverse event rates about on par with placebo, complement a previously-announced 4.8 month improvement in overall survival in the study.
Phase III Data AFFIRM Safety As Well As Survival For MDV3100
Medivation’s MDV3100 demonstrates a favorable safety profile and hits secondary efficacy endpoints in the AFFIRM study. Drug does not need to be given with prednisone, and could give J&J’s recently launched Zytiga a run for its money.